Agios Pharmaceuticals presented Phase 3 data from its RISE UP trial at the European Hematology Association (EHA) 2026 Plenary Session, underscoring the anti-hemolytic profile of mitapivat in patients with sickle cell disease (SCD). The results reinforce mitapivat's mechanism as a small-molecule activator of pyruvate kinase R (PKR), an enzyme central to red blood cell energy metabolism and membrane stability.
Mitapivat works by allosterically activating PKR, increasing ATP production within red blood cells and reducing the sickling cascade that drives chronic hemolysis in SCD. The RISE UP trial, a double-blind, placebo-controlled study, evaluated the compound's clinical endpoints including hemolysis biomarkers, hemoglobin levels, and patient-reported outcomes. The plenary presentation at EHA 2026 positions these findings among the field's most closely watched late-stage datasets in rare hematologic disease.
While mitapivat is a pharmaceutical compound rather than a dietary ingredient, the PKR activation pathway it targets has drawn parallel interest from the nutraceutical and functional food research community. Researchers investigating red blood cell resilience, oxidative stress reduction, and energy metabolism have cited enzymatic cofactor support — including riboflavin (vitamin B2), which is required for healthy erythrocyte function — as adjacent areas of formulation interest. Operators in the blood health and vitality segment and sports nutrition space have tracked this science for its downstream implications on oxygen-carrying capacity and anti-fatigue positioning.
The broader hemoglobin support and hematologic wellness category remains a developing niche within the functional nutrition market, with ingredient suppliers exploring structure-function claims around iron bioavailability, B-vitamin cofactors, and antioxidant support for red blood cell integrity. As pharmaceutical-grade data on PKR activation accumulates, it may inform future nutraceutical research directions, particularly for populations managing oxidative load or energy metabolism challenges.
Agios's continued investment in PKR science — mitapivat is already approved under the brand name Pyrukynd for pyruvate kinase deficiency — signals durable commercial and scientific interest in this enzymatic pathway. For functional food and supplement formulators monitoring the boundary between pharma-validated mechanisms and ingredient-level applications, the RISE UP readout is a data point worth tracking.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.